BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 12611065)

  • 1. Detection of relapse by sequential monitoring of chimerism in circulating CD34+ cells.
    Thiede Ch; Lutterbeck K; Oelschlägel U; Kiehl M; Steudel Ch; Platzbecker U; Brendel C; Fauser AA; Neubauer A; Ehninger G; Bornhäuser M
    Ann Hematol; 2002; 81 Suppl 2():S27-8. PubMed ID: 12611065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
    Kögler G; Hernandez A; Heyll A; Wolf HH; Wernet P
    Cancer Detect Prev; 1996; 20(6):601-9. PubMed ID: 8939346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia.
    Barrios M; Jiménez-Velasco A; Román-Gómez J; Madrigal ME; Castillejo JA; Torres A; Heiniger A
    Haematologica; 2003 Jul; 88(7):801-10. PubMed ID: 12857560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
    Elmaagacli AH; Runkel K; Steckel N; Opalka B; Trenschel R; Seeber S; Schaefer UW; Beelen DW
    Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT.
    Bader P; Beck J; Frey A; Schlegel PG; Hebarth H; Handgretinger R; Einsele H; Niemeyer C; Benda N; Faul C; Kanz L; Niethammer D; Klingebiel T
    Bone Marrow Transplant; 1998 Mar; 21(5):487-95. PubMed ID: 9535041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis.
    Hoffmann JC; Stabla K; Burchert A; Volkmann T; Bornhäuser M; Thiede C; Neubauer A; Brendel C
    Ann Hematol; 2014 Feb; 93(2):279-85. PubMed ID: 24352219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relapse of childhood ALL, AML and MDS after allogeneic stem cell transplantation can be prevented by donor lymphocyte infusion in a critical stage of increasing mixed chimerism].
    Beck JF; Klingebiel T; Kreyenberg H; Schaudt A; Wölle W; Niethammer D; Bader P
    Klin Padiatr; 2002; 214(4):201-5. PubMed ID: 12165902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Need for an accurate molecular diagnosis to assess the donor origin of leukemia relapse after allogeneic stem cell transplantation.
    Spinelli O; Giussani U; Borleri G; Lazzari M; Michelato A; Dotti G; Barbui T; Rambaldi A
    Haematologica; 2000 Nov; 85(11):1153-7. PubMed ID: 11064467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia.
    Kobbe G; Fenk R; Neumann F; Bernhardt A; Steidl U; Kondakci M; Graef T; Aivado M; Vaupel M; Huenerlituerkoglu AN; Kronenwett R; Pape H; Hildebrand B; Germing U; Haas R
    Cytotherapy; 2004; 6(6):533-42. PubMed ID: 15764020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse.
    Pulsipher MA; Bader P; Klingebiel T; Cooper LJ
    Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):62-71. PubMed ID: 19147081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early detection of relapse in patients with myelodysplastic syndrome after allo-SCT.
    Tobiasson M; Olsson R; Hellström-Lindberg E; Mattsson J
    Bone Marrow Transplant; 2011 May; 46(5):719-26. PubMed ID: 20697367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y-chromosome-specific sequences.
    Koldehoff M; Steckel NK; Hlinka M; Beelen DW; Elmaagacli AH
    Am J Hematol; 2006 Oct; 81(10):735-46. PubMed ID: 16838323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
    Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
    Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia.
    Zetterquist H; Mattsson J; Uzunel M; Näsman-Björk I; Svenberg P; Tammik L; Bayat G; Winiarski J; Ringdén O
    Bone Marrow Transplant; 2000 Apr; 25(8):843-51. PubMed ID: 10808205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning.
    Lange T; Hubmann M; Burkhardt R; Franke GN; Cross M; Scholz M; Leiblein S; Al-Ali HK; Edelmann J; Thiery J; Niederwieser D
    Leukemia; 2011 Mar; 25(3):498-505. PubMed ID: 21135860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic efficacy for measurement of real-time quantitative PCR-based major bcr/abl mRNA in patients with Philadelphia chromosome-positive leukemia].
    Takahata M; Hashino S; Fujisawa F; Kondo T; Ota S; Kobayashi S; Tanaka J; Imamura M; Asaka M
    Rinsho Ketsueki; 2004 Dec; 45(12):1241-6. PubMed ID: 15678915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Application of sequential and quantitative monitoring of chimerism in allogeneic hematopoietic stem cell transplantation].
    Tang XW; Wu DP; Zhu ZL; Wang W; Sun AN; Qiu HY; Fu ZZ; Chang WR; Ruan CG
    Zhonghua Xue Ye Xue Za Zhi; 2004 Feb; 25(2):78-81. PubMed ID: 14990044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.